Johnson & Johnson raised its full-year guidance after second-quarter sales grew nearly 7% to $25.31 billion, beating the $25.05 billion estimate, while Danaher cut the upper end of its core revenue growth outlook range to 4% from 6% following a quarter that BofA called messier than expected. Johnson & Johnson's pharmaceutical unit generated $16.38 billion in quarterly sales, exceeding the $16.1 billion estimate, as a 72.5% surge in Tremfya sales to $2 billion helped offset a more than 55% drop in Stelara revenue to $740 million due to patent loss. The company now expects annual sales of about $101.1 billion at the midpoint and raised its adjusted earnings per share forecast to $11.68 from $11.55. Danaher's Life Sciences business delivered its strongest performance in several years, with bioprocessing orders growing mid-teens, but weaker-than-expected biotechnology revenue and a shift of a little over $100 million in revenue into next year weighed on results. Hedge fund ownership of Johnson & Johnson rose to 113 in the first quarter of 2026 from 104 in the prior quarter, while Danaher's fell to 110 from 125, according to Insider Monkey data.
Johnson & JohnsonJohnson & Johnson raised full-year guidance and adjusted EPS forecast after beating Q2 estimates.
Danaher CorporationDanaher cut its core revenue growth outlook to 4% from 6% after a messy quarter with weaker biotech revenue.